Photo by Petr Magera on Unsplash
- A December 2024 federal court decision struck down USDA's 2020 SECURE rule, sending agricultural biotech oversight back to older, more burdensome pre-2020 standards under 7 CFR Part 340.
- USDA APHIS published Federal Register RFI Doc No. 2026-09833 on May 15, 2026, opening a 30-day public comment period that closes June 15, 2026.
- The regulatory vacuum rattles a global market estimated at USD 172.07 billion in 2026 — projected to hit USD 283.61 billion by 2033 — even as China outpaces combined U.S., India, and Brazil agricultural R&D investment.
- Biotech developers, seed companies, and agricultural businesses should file formal comments, audit compliance exposure under pre-2020 standards, and monitor APHIS's anticipated interim final rule targeting low-risk organisms.
What Happened
Thirty days. That is the window federal regulators have given the public to help determine how the next generation of genetically modified crops and microbes will be overseen in the United States — and that clock started ticking on May 15, 2026.
According to The National Law Review, USDA's Animal and Plant Health Inspection Service (APHIS) posted a formal Request for Information (Federal Register Doc No. 2026-09833) titled "Request for Information on Modified Organisms Subject to the Plant Protection Act," with public comments due by June 15, 2026.
The RFI did not arrive without context. It is the direct institutional consequence of a federal district court ruling issued December 2, 2024, in National Family Farm Coalition v. Vilsack, in which the U.S. District Court for the Northern District of California vacated USDA's 2020 SECURE (Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient) rule. That rule had established cleaner oversight pathways for genetically engineered organisms under 7 CFR Part 340, introducing risk-calibrated exemptions and predictable developer timelines. The court struck it down on the grounds that APHIS acted arbitrarily and capriciously: the agency failed to incorporate its noxious-weed authority into the rule's design, and it extended conventional-breeding exemptions beyond what the Plant Protection Act (PPA) explicitly authorizes. With the SECURE rule gone, regulatory standards reverted to their pre-2020 form.
Now APHIS is asking a structurally significant question in the RFI: should modified organisms be regulated under 7 CFR Part 330, which governs plant pests and related articles, rather than remaining under Part 340? The answer carries sweeping legal, commercial, and trade implications across the entire agricultural biotech sector. Regulatory analysts at ArentFox Schiff — lawyers who specialize in tracking these developments — characterized the May 2026 RFI as "much-anticipated," noting that APHIS is specifically exploring deregulatory frameworks for modified microorganisms, a category the vacated SECURE rule never directly addressed. A separate anticipated rulemaking, listed in the Spring 2025 Unified Regulatory Agenda as "Regaining Lost Efficiencies for Products of Biotechnology," is projected for 2026 publication and would target exemptions and simplified procedures for lower-risk plants and microbes.
Photo by Daniil Komov on Unsplash
Why It Matters for You
Think of agricultural biotech regulation the way a contractor thinks about building permits. When permit categories are clear and predictable, developers can sequence investments, schedule timelines, and move products from lab to market with confidence. When a court voids the permit framework mid-project, capital freezes and timelines stretch until a new structure emerges. That is precisely the position the agricultural biotech sector occupies today.
The stakes are not abstract. The global agricultural biotechnology market was estimated at USD 172.07 billion in 2026, with nutritionally enhanced genetically modified seeds and crops holding the largest individual segment at a 50.3% share, while genetic engineering technology leads product categories at 32.2% of the market, according to data from Coherent Market Insights. Analysts project total market size will expand to USD 283.61 billion by 2033 at a compound annual growth rate (CAGR — the year-over-year average growth percentage across the full period) of 7.4%. Regulatory instability of the kind created by National Family Farm Coalition v. Vilsack injects uncertainty into product development pipelines and slows investment decisions, putting downward pressure on that growth curve.
Chart: The agricultural biotechnology market is on track to grow by more than $111 billion over seven years — a trajectory that presupposes stable regulatory conditions that do not currently exist.
There is a national security dimension layered underneath the market projections. The National Security Commission on Emerging Biotechnology (NSCEB) has published analysis outlining 83 distinct policy options for modernizing U.S. biotech oversight, warning that competitive positioning is eroding. Between 2019 and 2021, China directed more public funding into agricultural research and development than the United States, India, and Brazil combined. U.S. total factor agricultural productivity growth — a measure of how efficiently the sector converts land, labor, and capital into output — has also trailed those same three nations over the preceding decade. For biotech businesses, this creates dual urgency: resolve the domestic regulatory uncertainty while preventing regulatory drag from handing overseas competitors a structural advantage.
The Breakthrough Institute, a policy research organization, offered a notably optimistic framing of the current moment. Rather than treating the court's decision as purely a setback for industry, its analysts argued that "the SECURE rule vacature creates an opportunity for USDA to develop improved product- and risk-based agricultural biotechnology regulations" — treating the regulatory reset as a genuine opening to build something more scientifically grounded than what preceded it. The statute that governs all of this — the Plant Protection Act — gives APHIS authority to regulate organisms that could constitute plant pests or noxious weeds. The court's core finding was that APHIS wrote exemptions the PPA does not authorize, and failed to engage its noxious-weed mandate. Any successor rule must stay within those statutory walls, or Congress will need to expand them.
The AI Angle
The intersection of biotechnology and artificial intelligence is reshaping agricultural supply chains at every level, from genomic sequencing to predictive crop modeling. That convergence makes regulatory clarity a legal technology question as much as a policy one. When a firm is using AI legal tools to model compliance risk across a product development portfolio, a court ruling that voids the foundational framework cascades into errors across every downstream analysis that relied on it.
Larger law firms advising agribusiness clients are increasingly deploying law firm automation platforms to monitor Federal Register publications like this RFI in real time, flag comment deadlines, and help structure formal submissions. Contract review systems — specialized legal software that parses regulatory language for compliance exposure — are already being calibrated to map the divergence between the 7 CFR Part 340 and Part 330 frameworks, identifying which provisions survive the SECURE rule's vacatur and which are now in limbo. ArentFox Schiff's analysis of the May 2026 RFI represents the kind of real-time regulatory intelligence that law firm automation makes scalable at a practice level. For smaller developers without equivalent resources, AI legal tools built on open regulatory databases offer partial substitutes for tracking these developments — though they are not a replacement for qualified counsel navigating a structurally unsettled regulatory landscape. Contract review capabilities, in particular, can help compliance teams rapidly audit product approval documents against pre-2020 standards to identify exposure gaps.
What Should You Do? 3 Action Steps
APHIS RFI Doc No. 2026-09833 is open on the Federal Register for comment through June 15, 2026. Any stakeholder — seed company, biotech developer, farmer cooperative, university research program, or trade organization — can submit formal input on whether modified organisms should move from Part 340 to Part 330, and what a risk-proportionate framework should require. Agencies are legally obligated to consider substantive comments received during an open rulemaking window. If your business is directly affected by GE organism oversight, remaining silent during this comment period is not a neutral act — it cedes the rulemaking conversation to others whose interests may differ from yours.
With the SECURE rule vacated, any product that received streamlined treatment under the 2020 framework may now require more intensive APHIS review under the reverted 7 CFR Part 340 standards. Compliance teams should map current product approvals and pending applications against pre-2020 requirements. Legal software platforms and contract review tools can help accelerate this gap analysis by flagging regulatory language differences, but the strategic decisions should involve qualified regulatory counsel familiar with APHIS's enforcement history and the specific plant-pest and noxious-weed authority at issue under the PPA. Before you sign any new licensing or development agreements that assume current regulatory status, understand which approvals may now be vulnerable to additional scrutiny.
APHIS listed an anticipated interim final rule titled "Regaining Lost Efficiencies for Products of Biotechnology" in the Spring 2025 Unified Regulatory Agenda, with publication targeted for 2026. This rule is expected to establish exemptions or simplified procedures for lower-risk plants and microorganisms — the practical successor to the efficiency gains the SECURE rule was designed to deliver, constrained within the statutory limits the court identified. Subscribing to the Unified Regulatory Agenda update feed and engaging with this rulemaking when it publishes is the single highest-leverage regulatory action most agricultural biotech businesses can take in the near term. A court would likely look at the new rule's conformance with the PPA's plain text as the central legal test — businesses whose products fit squarely within statutory plant-pest categories will be positioned better than those relying on broader conventional-breeding analogies.
Frequently Asked Questions
What does it mean for biotech developers that the SECURE rule was vacated by a federal court in 2024?
The December 2, 2024 ruling in National Family Farm Coalition v. Vilsack eliminated the streamlined oversight framework USDA built for genetically engineered organisms beginning in 2020. In operational terms, companies that relied on simplified review pathways created by the SECURE rule now face the more burdensome pre-2020 standards under 7 CFR Part 340 — at least until USDA finalizes a replacement. The court found APHIS acted arbitrarily by exceeding the Plant Protection Act's boundaries, so any successor rule must stay within those statutory limits or secure a congressional expansion of APHIS authority. Products in development pipelines should be reviewed for regulatory exposure immediately.
How would a shift from 7 CFR Part 340 to Part 330 affect agricultural biotechnology product approvals?
This is the central structural question USDA's May 2026 RFI is designed to answer with stakeholder input. Part 330 governs movement and handling of plant pests and related articles, while Part 340 has been the dedicated home of GE organism oversight. Migrating jurisdiction could alter notification requirements, inspection procedures, the legal basis for category exemptions, and the framework's international trade compatibility. For developers, this is not an administrative housekeeping move — it could materially change compliance timelines and the evidentiary burden for new product approvals across the sector.
Can AI legal tools help agricultural biotech companies track USDA regulatory changes without hiring additional staff?
To a meaningful degree, yes. Law firm automation platforms and AI-powered legal software can monitor Federal Register publications in real time, flag comment deadlines like the June 15, 2026 cutoff, and help legal teams draft structured regulatory submissions. Some contract review systems are being trained on the Part 340 versus Part 330 regulatory divergence as APHIS develops its new approach. That said, these tools work best alongside qualified counsel familiar with APHIS's enforcement history and the specific noxious-weed and plant-pest authority at issue under the Plant Protection Act. AI legal tools reduce research overhead — they do not replace statutory interpretation judgment.
How does U.S. agricultural biotech regulatory instability compare to what competitors like China are experiencing?
The competitive gap is widening in ways that national security analysts have flagged as urgent. The National Security Commission on Emerging Biotechnology identified that between 2019 and 2021, China's public agricultural R&D investment exceeded the combined expenditure of the U.S., India, and Brazil. U.S. total factor agricultural productivity growth — how efficiently the sector converts inputs into outputs — has also trailed all three of those countries over the past decade. With the global agricultural biotech market projected to grow from roughly $172 billion today to over $283 billion by 2033, regulatory uncertainty is a competitiveness variable that affects market share, not just compliance costs.
What is the Plant Protection Act and why is it the legal foundation for USDA agricultural biotech reform?
The Plant Protection Act (PPA) is the primary federal statute authorizing USDA APHIS to regulate organisms that pose risks to U.S. agriculture, covering both plant pests and noxious weeds. It is the legal foundation for everything APHIS does in the genetically engineered organism space. The SECURE rule was vacated specifically because the court found that APHIS exceeded what the PPA authorizes: the conventional-breeding exemptions went further than the statute permits, and the agency failed to engage its noxious-weed regulatory mandate when constructing the rule. The statute reads as a bounded grant of authority — not an open-ended one — and USDA's next regulatory framework must be designed accordingly, or face the same legal vulnerability in future litigation.
Disclaimer: This article is for informational and educational purposes only and does not constitute legal advice. Regulations, statutory interpretations, and legal standards referenced herein may change. Consult qualified legal counsel for guidance specific to your regulatory situation.